<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Biotek-snakken — Oktober 2017]]></title><description><![CDATA[<p dir="auto">Er der nogle der har kigget på Bergenbio? Økonomisk Ugebrev omtaler dem særdeles positivt.</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/401365/biotek-snakken-oktober-2017</link><generator>RSS for Node</generator><lastBuildDate>Mon, 08 Jun 2026 04:15:30 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/401365.rss" rel="self" type="application/rss+xml"/><pubDate>Tue, 03 Oct 2017 05:08:27 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Mon, 30 Oct 2017 09:33:06 GMT]]></title><description><![CDATA[<p dir="auto">Men der ligger så vidt jeg ved endnu ikke et prospekt klar. Nogen der har en ide om, hvad prisfastsættelsen af selskabet bliver og, hvor stor en del af aktierne der sættes fri? (bemærk vi kan ikke bruge de 600 mio. de vil sælge aktier for til andet end at sige, at prisfastsættelsen i hvert fald bliver derover)</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056833</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056833</guid><dc:creator><![CDATA[The_Jokers]]></dc:creator><pubDate>Mon, 30 Oct 2017 09:33:06 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Mon, 30 Oct 2017 09:30:16 GMT]]></title><description><![CDATA[<p dir="auto">Expres2ion fortsætter opad. Der er virkelig mange som gerne vil ind i aktien i disse uger.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056834</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056834</guid><dc:creator><![CDATA[nik_hs1990]]></dc:creator><pubDate>Mon, 30 Oct 2017 09:30:16 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Mon, 30 Oct 2017 09:29:49 GMT]]></title><description><![CDATA[<p dir="auto">Tænker at jeg gerne vil tegne et lille frimærke i Orphazyme. Tror interessen vil være stor for selskabet, da de har en meget interessant pipeline.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056830</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056830</guid><dc:creator><![CDATA[nik_hs1990]]></dc:creator><pubDate>Mon, 30 Oct 2017 09:29:49 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Sat, 28 Oct 2017 04:18:04 GMT]]></title><description><![CDATA[<p dir="auto"><a class="plugin-mentions-user plugin-mentions-a" href="/forum/user/molira" aria-label="Profile: Molira">@<bdi>Molira</bdi></a> - du skal sende en mail til din bankmand, om hvor mange aktier du ønsker, og hvilken max. kurs du vil betale. Handler du hos Nordnet, så mener jeg, de plejer at lægge en formular på hjemmesiden, som du blot skal udfylde og trykke "send" på.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056832</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056832</guid><dc:creator><![CDATA[Tyndeejner]]></dc:creator><pubDate>Sat, 28 Oct 2017 04:18:04 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Fri, 27 Oct 2017 10:20:33 GMT]]></title><description><![CDATA[<p dir="auto">Hvordan får man bestilt Orphazyme aktier til børsnoteringen?</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056831</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056831</guid><dc:creator><![CDATA[Molira]]></dc:creator><pubDate>Fri, 27 Oct 2017 10:20:33 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Fri, 27 Oct 2017 07:07:14 GMT]]></title><description><![CDATA[<p dir="auto">Nuevolution: hvad er status på den patentretssag, som den tidligere medejer ser ud til at have vundet 2016? Skal vi forvente, at nuevo skal betale royalties eller at de risikerer at blive stoppet i anvendelse af patenterne? anyone?</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056826</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056826</guid><dc:creator><![CDATA[DevOp]]></dc:creator><pubDate>Fri, 27 Oct 2017 07:07:14 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Thu, 26 Oct 2017 09:22:38 GMT]]></title><description><![CDATA[<p dir="auto">Ser ud som om det er blevet afbrudt for at efterforske en række mulige voldsomme bivirkninger.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056828</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056828</guid><dc:creator><![CDATA[JohnW]]></dc:creator><pubDate>Thu, 26 Oct 2017 09:22:38 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Thu, 26 Oct 2017 09:19:20 GMT]]></title><description><![CDATA[<p dir="auto">Saniona har det lidt svært i dag efter at fase 2 er afsluttet ?</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056829</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056829</guid><dc:creator><![CDATA[henrik48]]></dc:creator><pubDate>Thu, 26 Oct 2017 09:19:20 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Thu, 26 Oct 2017 06:28:52 GMT]]></title><description><![CDATA[<p dir="auto">BerGenBio er kommet med en stribe positive nyheder hér i Oktober bl.a. vedr. opstart af fase 2 forsøg. Alligevel er aktien faldet 15 den sidste måneds tid. Er der nogle der ved hvorfor?</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056823</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056823</guid><dc:creator><![CDATA[JohnW]]></dc:creator><pubDate>Thu, 26 Oct 2017 06:28:52 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Wed, 25 Oct 2017 04:43:47 GMT]]></title><description><![CDATA[<p dir="auto">?</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056820</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056820</guid><dc:creator><![CDATA[Sukkeralf]]></dc:creator><pubDate>Wed, 25 Oct 2017 04:43:47 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Wed, 25 Oct 2017 04:43:43 GMT]]></title><description><![CDATA[<p dir="auto">Nogen der kender BergenBio+</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056821</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056821</guid><dc:creator><![CDATA[Sukkeralf]]></dc:creator><pubDate>Wed, 25 Oct 2017 04:43:43 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 24 Oct 2017 10:55:07 GMT]]></title><description><![CDATA[<p dir="auto">Pipeline ser spændende ud.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056827</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056827</guid><dc:creator><![CDATA[nik_hs1990]]></dc:creator><pubDate>Tue, 24 Oct 2017 10:55:07 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 24 Oct 2017 10:54:59 GMT]]></title><description><![CDATA[<p dir="auto">Expres2ion leverer igen idag en forrygende stigning.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056824</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056824</guid><dc:creator><![CDATA[nik_hs1990]]></dc:creator><pubDate>Tue, 24 Oct 2017 10:54:59 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 24 Oct 2017 07:47:35 GMT]]></title><description><![CDATA[<p dir="auto">Orphazyme virker spændende da de har 3 kandidater klar til opstart i Fase 3.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056818</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056818</guid><dc:creator><![CDATA[nik_hs1990]]></dc:creator><pubDate>Tue, 24 Oct 2017 07:47:35 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 24 Oct 2017 05:34:02 GMT]]></title><description><![CDATA[<p dir="auto">Oppe med 7,5 % -</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056817</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056817</guid><dc:creator><![CDATA[nohope]]></dc:creator><pubDate>Tue, 24 Oct 2017 05:34:02 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 24 Oct 2017 05:30:10 GMT]]></title><description><![CDATA[<p dir="auto">MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to MOR208, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not eligible for high-dose chemotherapy and autologous stem-cell transplantation</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056815</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056815</guid><dc:creator><![CDATA[nohope]]></dc:creator><pubDate>Tue, 24 Oct 2017 05:30:10 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 24 Oct 2017 04:15:07 GMT]]></title><description><![CDATA[<p dir="auto">Nej intet, desværre. Mon ikke der kommer fokus på selskabet de kommende uger?</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056816</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056816</guid><dc:creator><![CDATA[JKY_VH]]></dc:creator><pubDate>Tue, 24 Oct 2017 04:15:07 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 24 Oct 2017 03:48:37 GMT]]></title><description><![CDATA[<p dir="auto"><a class="plugin-mentions-user plugin-mentions-a" href="/forum/user/jky_vh" aria-label="Profile: JKY_VH">@<bdi>JKY_VH</bdi></a> kender du noget til selskabet, ud over hvad man kan læse i avisen?</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056813</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056813</guid><dc:creator><![CDATA[Tyndeejner]]></dc:creator><pubDate>Tue, 24 Oct 2017 03:48:37 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 24 Oct 2017 03:34:50 GMT]]></title><description><![CDATA[<p dir="auto">Orphazyme har desuden en strategi om selv at stå for salget i stedet for at sælge rettighederne videre til større medicinalfirmaer.</p>
<p dir="auto">/ritzau/FINANS</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056822</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056822</guid><dc:creator><![CDATA[JKY_VH]]></dc:creator><pubDate>Tue, 24 Oct 2017 03:34:50 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 24 Oct 2017 03:34:46 GMT]]></title><description><![CDATA[<p dir="auto">Biotekselskabet Orphazyme meldes klar til at ramme fondsbørsen i København til november. Det skriver dagbladet Børsen med henvisning til anonyme kilder.</p>
<p dir="auto">Orphazyme vil angiveligt sælge aktier for 600 mio. kr., og det bliver første gang, der skal nynoteres et biotekselskab i Danmark siden Zealand Pharma i 2010.</p>
<p dir="auto">Pengene skal ifølge Børsen bruges til at gennemføre de sidste kliniske studier med lægemidler mod to muskelsvindssygdomme.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056808</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056808</guid><dc:creator><![CDATA[JKY_VH]]></dc:creator><pubDate>Tue, 24 Oct 2017 03:34:46 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Mon, 23 Oct 2017 10:51:31 GMT]]></title><description><![CDATA[<p dir="auto">Glem linket. Det er ikke relevant</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056819</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056819</guid><dc:creator><![CDATA[bibob]]></dc:creator><pubDate>Mon, 23 Oct 2017 10:51:31 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Mon, 23 Oct 2017 10:50:12 GMT]]></title><description><![CDATA[<p dir="auto"><a href="https://european-biotechnology.com/up-to-date/latest-news/news/adc-therapeutics-raises-us200m-in-private-" rel="nofollow ugc">https://european-biotechnology.com/up-to-date/latest-news/news/adc-therapeutics-raises-us200m-in-private-</a><br />
financing.html</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056812</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056812</guid><dc:creator><![CDATA[bibob]]></dc:creator><pubDate>Mon, 23 Oct 2017 10:50:12 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 17 Oct 2017 17:03:25 GMT]]></title><description><![CDATA[<p dir="auto">Er uforudsigeligt</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056814</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056814</guid><dc:creator><![CDATA[bibob]]></dc:creator><pubDate>Tue, 17 Oct 2017 17:03:25 GMT</pubDate></item><item><title><![CDATA[Reply to Biotek-snakken — Oktober 2017 on Tue, 17 Oct 2017 17:03:03 GMT]]></title><description><![CDATA[<p dir="auto">Biotech</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8056809</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8056809</guid><dc:creator><![CDATA[bibob]]></dc:creator><pubDate>Tue, 17 Oct 2017 17:03:03 GMT</pubDate></item></channel></rss>